High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria.

@article{Samaniego2011HighRR,
  title={High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria.},
  author={Felipe Samaniego and Fredrick B. Hagemeister and Peter Mclaughlin and Larry W. Kwak and Jorge E Romaguera and Michelle A Fanale and Sattva S. Neelapu and Luis E. Fayad and Robert Z. Orlowski and Michael C. Wang and L Lacerte and Nathan H Fowler},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={8030}
}
8030 Background: Lenalidomide has been shown to have single-agent activity in relapsed NHL, and rituximab (R) is effective alone and in combination with chemotherapy in untreated patients. The aim of this phase II, single arm study is to evaluate the efficacy and safety of lenalidomide and rituximab in pts with untreated, advanced stage, indolent NHL. METHODS Pts with measurable (>1.5 cm) untreated indolent NHL received 20 mg/day of lenalidomide on days 1-21 and rituximab 375 mg/m2 on day 1… CONTINUE READING

Similar Papers

Loading similar papers…